Q-omics provides the consensus-scored MINPP1 profile across patient tissues and cancer cell-line models. MINPP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MINPP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MINPP1 protein abundance shows 20,681 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where MINPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MINPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MINPP1 survival associations across molecular data types. MINPP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MINPP1 RNA expression–survival associations across cancer types. High MINPP1 expression shows unfavorable associations in HNSC, KIRP, ACC and UVM, but favorable associations in UCS and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MINPP1 RNA expression.
This table summarizes MINPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MINPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MINPP1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, KIRC and LUAD. The HNSC box plot shows higher MINPP1 RNA expression in tumor versus normal tissue (log2 FC = +1.440, t-test p < 0.001).
This table shows molecular features associated with MINPP1 in patient tissues and cancer cell lines. In patient samples, MINPP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MINPP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
